Archive for Октябрь, 2008
Regulators Will Be Wary in Weighing Up Acomplia
The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti–obesity drug Acomplia, it can expect close scrutiny during the approval process of the side effects.
Want to lose weight, stop smoking and cut [...]
Sanofi Allowed to Inform Patients Taking Acomplia That It Aids Blood Sugar Control
The European Commission has decided to let Sanofi-Aventis inform patients taking diet drug Acomplia (rimonabant) that the pill may also help in diabetic blood sugar control, but that does not mean it is approved to be prescribed as a diabetes drug.
The announcement, which ratified an [...]
Diet Drug Acomplia Found to Up Risk of Anxiety and Depression in Heart Study
Diet drug rimonabant (Acomplia / Zimulti ) produced disappointing results in slowing progression of coronary artery disease in patients and it significantly raised the risk of anxiety and depression, according to a report in the April 2 issue of the Journal of the American Medical Association.
[...]
Obesity Expert Hails Acomplia Trial Results as Potentially “Major Advance”
Dr Nick Finer, consultant in obesity medicine at Addenbrooke’s Hospital in Cambridge Acomplia (rimonabant) , who was involved in the study on diabetic patients, said the drug “could be a major advance in the management, not just of obesity, but of the risk factors of obesity”.
[...]
Sanofi-Aventis, developer of diet drug Acomplia (rimonabant) (Acomplia / Zimulti), said on May 24th it was “examining all legal options” in light of the emergence of three different companies offering generic versions of rimonabant in India.
The development puts Sanofi in the odd position of facing generic competition [...]
Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center
"Acomplia’s been given to 13,000 people but you just don’t completely know what happens when you give it to a million.”
Dr. Louis J. Aronne, New York Hospital - Cornell Medical Center, quoted on June 28, 2006 by
Bloomberg
Acomplia Report Newsletter Is Renamed the Zimulti Acomplia
The Acomplia (rimonabant) since 2004 the only independent newsletter reporting on the development of diet drug Acomplia (rimonabant), announced today that effective immediately, the online newsletter will be named the Acomplia
The name change was made after the U.S. Food and Drug Administration and manufacturer Sanofi-Aventis [...]
FDA Delay on Diet Pill Acomplia (Rimonabant) Tied to Suicide, Seizures
The long delay in FDA action on diet drug rimonabant ( Acomplia (rimonabant) is the result of concern over “increased frequencies of psychiatric adverse effects” including suicide and seizures, the agency’s staff disclosed on June 11th.
The confirmation of long-rumored FDA worries over the neuropsychiatric side-effects of [...]
